Vital Therapies slashes staff; Presbia closes in on U.S. pivotal trial completion;

@FierceMedDev: Focus Diagnostics gets FDA blessing to expand label for herpes test. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: Philips unveils consumer, connected health bid featuring app and 5 devices, including watch. Story | Follow @StacyALawrence

@EmilyWFierce: Report: C.R. Bard downplayed serious problems related to blood-clot device. Article | Follow @EmilyWFierce

> Micro-cap Vital Therapies ($VTL) will cut 30% of its work force to better conserve capital. Its clinical stage ELAD system to treat lever failure is in multiple clinical trials; it's an external blood filtration system that incorporates liver cells into fiber-filled cartridges. More

> Thoratec ($THOR) has started its SHIELD II U.S. clinical trial for its HeartMate PHP in patients undergoing a high-risk percutaneous coronary intervention (PCI) procedures. More

> Presbia ($LENS) has almost completed enrollment for the second stage of enrollment of 337 patients in its U.S. pivotal study Presbia Flexivue Microlens to treat presbyopia. The final surgeries are slated for the week of Sept. 7. More

Biotech News

@FierceBiotech: The 2015 Fierce 15 will be announced in a few weeks. Celebrate the winners with us in October at #BIF15. More | Follow @FierceBiotech

@JohnCFierce: Fibrodysplasia ossificans progressive gets my vote as one of the world's creepiest deadly diseases. Tissue to bone. More | Follow @JohnCFierce

> Roche gets a 'breakthrough' at the FDA for a top PhIII development effort. Article

> Alexion runs into an FDA delay with its latest rare disease drug. Story

FierceBiotech Radio on Valeant's fantasy football M&A, the gathering PCSK9 storm, and Novartis' alarming new campaign. Listen

Pharma News

@FiercePharma: Pharma market bets on ASEAN in focus ahead of economic pact. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Last week, Novo announced huge production build-up. This week a warehouse for the raw materials. More from FiercePharmaManutacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do? More | Follow @CarlyHFierce

> Undeterred by PTO setbacks, Bass slaps new challenges on Acorda patents. Report

> Ka-Ching: F. Michael Ball cashes out of Hospira with $91.1M. More

> AstraZeneca scores FDA nod for long-term Brilinta use. Story

> Novartis snags EU approval for multiple myeloma med Farydak. Article

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.